Klaria Pharma Holding
0,546 SEK -9,6%1 investor følger denne virksomhed
Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient's oral mucosa, which enables the distribution of pharmaceuticals in the body. The head office is located in Uppsala.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
KLAR
Daglig lav / høj pris
0,526 / 0,56
SEK
Markedsværdi
79,04 mio. SEK
Aktieomsætning
66,03 t SEK
Volumen
121 t
Finanskalender
Delårsrapport
21.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Ålandsbanken | 6,7 % | 6,7 % |
Skandinaviska Enskilda Banken | 4,3 % | 4,3 % |
Promenaden Invest AB | 3,8 % | 3,8 % |
Djerdu Invest AB | 3,8 % | 3,8 % |
Jack Weil | 3,8 % | 3,8 % |
Fredrik Hübinette | 3,6 % | 3,6 % |
Sven-Olov Hjälmstad | 3,5 % | 3,5 % |
Buntel AB | 3,5 % | 3,5 % |
Munkekullen Förvaltnings AB | 3,5 % | 3,5 % |
Banque Pictet & CIE | 3,3 % | 3,3 % |
ViserAlle indholdstyper
Klaria Pharma Holding AB: Klaria Interim Report Q2 2024
Klaria Pharma Holding AB: Klaria Sumatriptan Alginate Film Receives Marketing Authorization
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools